XOMA CORP (XOMA)
US98419J2069 - Common Stock
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage...
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or...
Actym Therapeutics Appoints Thomas Smart as CEO
/PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive...
XOMA Corporation Announces Closing of Tender Offer
Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right
XOMA Corporation Announces Closing of Tender Offer
XOMA completes acquisition of Kinnate....
XOMA Declares Quarterly Preferred Stock Dividends
XOMA Declares Quarterly Preferred Stock Dividends
April 2024 quarterly dividend...
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
Pricing of Kinnate acquisition...
XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips XOMA (NASDAQ:XOMA) just reported results for the fourth quarter of 2023.XOMA re...
XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023
XOMA stock results show that XOMA missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital ...
XOMA to Present at Upcoming Investor Conferences in March
XOMA to Present at Upcoming Investor Conferences in March
EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its...
Xoma to acquire Kinnate Biopharma (NASDAQ:XOMA)
XOMA Corporation (XOMA) announces plans to acquire Kinnate Biopharma (KNTE) for $2.3352-$2.5879 per share in cash, with a contingent value right. Read more here.
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
XOMA enters agreement to acquire Kinnate for cash and CVR; Expects to add $9.5M cash to balance sheet upon completion of acquisition...
XOMA expands portfolio with DSUVIA acquisition; shares tick lower (NASDAQ:XOMA)
XOMA Corp acquires an economic interest in DSUVIA for $8 million, expanding their portfolio.
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial sales and a...
Xoma to pay $1M to LadRx as FDA reviews arimoclomol
Xoma Corporation (XOMA) will pay $1M to LadRx Corporation (LADX) as FDA accepted the marketing application for rare disease therapy arimoclomol. Read more here.
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of June 21, 2024
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of June 21, 2024...
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
XOMA appoints Owen Hughes as CEO...
XOMA announces stock repurchase program of up to $50M (NASDAQ:XOMA)
XOMA Corporation announces its first stock repurchase program of up to $50M, driving a positive market reaction with a 5.41% increase in stock price.
XOMA Announces Stock Repurchase Program of up to $50 Million
Balanced capital allocation strategy looks to return capital to shareholders while continuing to invest in royalty and milestone acquisitions that will drive total shareholder return
XOMA Announces Stock Repurchase Program of up to $50 Million
XOMA to repurchase up to $50M of its stock before January 2027. Management actively participating in capital structure to maximize shareholder value. ...
XOMA Declares Quarterly Preferred Stock Dividends
XOMA Declares Quarterly Preferred Stock Dividends
January quarterly dividend payment to XOMAP and XOMAO stockholders of record on 1/3/2024...